Among m6A modification regulatory factors, METTL3 has been thoroughly and extensively studied in the progression of various cancer types, with multiple studies confirming METTL3 as an independent prognostic factor significantly associated with survival rates in NPC patients 37, 38. This evidence concerns the gene METTL3 and cancer.